Real-world natalizumab biosimilar switching preserved relapsing-remitting MS outcomes but lowered treatment satisfaction, ...

A romosozumab biosimilar showed comparable sclerostin binding and bone-signaling potency to the reference product despite disulfide isoform differences. A romosozumab biosimilar in late-stage ...

Early use of ustekinumab biosimilars in Spain shows cost-effective Crohn disease care, boosting QALYs and cutting NHS spend—insights for Europe. Patients with moderate to severe Crohn disease in Spain ...

Biosimilar anti-VEGF agents matched the reference ranibizumab in vision outcomes and safety across retinal diseases in India, at a lower cost. More than half of India's health care spending is paid ...

Real-world data shows rituximab biosimilars for membranous nephropathy match remission rates, cut costs, and expand treatment options. A lower-cost biosimilar of rituximab produced remission rates on ...

Trial data show switching between ABP 654 and reference ustekinumab maintains similar psoriasis control, safety, and ...

Regeneron appeals legal decision after judge refuses to block an aflibercept biosimilar; Prime Therapeutics, a pharmacy benefit manager (PBM), becomes the latest to offer biosimilars referencing ...

Phase 3 data show denosumab biosimilar KN012 matches Prolia for BMD gains and safety, potentially expanding affordable osteoporosis care. For postmenopausal women managing osteoporosis, the high cost ...

Global review reveals uneven biosimilar rules on waivers, interchangeability, and safety tracking—barriers to cheaper biologics and approvals. Wide variation in how countries define, evaluate, and ...

FDA expands Tofidence uses, Teva launches Eylea biosimilar in Europe, and Alvotech’s Entyvio rival enters FDA review—boosting access. Biosimilar developers across the globe advanced their pipelines ...